Sanofi and Regeneron Seal Eight Billion Dollar Deal
Sanofi and Regeneron have expanded their partnership through an eight billion dollar agreement to develop four new drugs and settle prior litigation. The deal includes one billion upfront and marks a strategic reset under Sanofi's new leadership.
Xurve View
Insights:
Xurve View
Sanofi and Regeneron Pharmaceuticals agreed to develop four new drugs together in an $8B deal on Thursday, settling prior litigation. The agreement resets the strained partnership of the France-based firm and its United States collaborator. The pact delivers an early strategic win for Sanofi's chief executive.
